Palisade bio reports third quarter 2022 financial results and provides business update

Carlsbad, ca, nov. 14, 2022 (globe newswire) -- palisade bio, inc. , (nasdaq: pali) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications (the “company” or “palisade”), reported its financial results for the quarter ended september 30, 2022. the company also provided an update on the status of its clinical development programs for lb1148.
PALI Ratings Summary
PALI Quant Ranking